You should contact your GP or diabetes specialist nurse if: Weakness is severe, persistent, or progressively worsening You experience recurrent episodes of hypoglycaemia (blood glucose below 4 mmol/L) [13] Weakness is accompanied by chest pain, shortness of breath, or palpitations You have significant muscle weakness affecting mobility or daily activities Gastrointestinal symptoms (nausea, vomiting, diarrhoea) are severe or prolonged, leading to dehydration You notice unexplained weight loss beyond what is expected with treatment You develop symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back) You experience right upper quadrant pain, fever or jaundice (possible gallbladder issues) You notice new or sudden changes in your vision You have reduced urine output or confusion (possible dehydration or kidney problems) Contact NHS 111 for urgent but non-life-threatening concerns, or seek emergency care (call 999 or attend A&E) if: You experience symptoms of severe hypoglycaemia with confusion, loss of consciousness, or seizures You have signs of severe dehydration (extreme dizziness, reduced urine output, rapid heartbeat) You develop symptoms suggestive of diabetic ketoacidosis (though rare with GLP-1 receptor agonists like Ozempic), such as abdominal pain, vomiting, rapid breathing, and ketones in blood or urine [23] [24] Your healthcare provider can conduct a thorough assessment, including blood tests to evaluate glucose control, electrolyte balance, kidney function, and thyroid status
"Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell): review by two specialists is required for initiating valproate but not for male patients already taking valproate"
If anybody could look me up up in five-- whoever's targeting me probably had five minutes to look me up
460, 493 Resl, M
The health benefits Thomas Ryder, Managing Director at Applied Nutrition, says: Were excited to be bringing Carni-Tone to the market following one of our longest product development cycles
Tomomi Furihata, Tokyo University of Pharmacy and Life Sciences
